Ondansetron Pliva Pharma (Ondansetron)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. This inhibition stops serotonin‑mediated signaling that normally triggers the vomiting reflex, thereby reducing nausea and vomiting associated with cancer therapies and surgery.

The dose of ondansetron is individualized by the prescribing clinician based on the indication, patient age, weight and renal function. Healthcare professionals determine the appropriate strength and frequency according to approved guidelines and the patient’s specific therapeutic needs.

Ondansetron is classified as Pregnancy Category B in many regions, indicating no proven risk in animal studies but limited human data. It may be used during pregnancy only when the potential benefit outweighs any possible risk. Small amounts are excreted in breast milk, so breastfeeding mothers should discuss use with a healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, offering rapid onset and effective control of both acute and delayed nausea. Compared with dopamine antagonists such as metoclopramide, ondansetron has a lower risk of extrapyramidal side effects and is often preferred for chemotherapy‑induced nausea.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Ondansetron Pliva Pharma is supplied as oral tablets that are swallowed whole with water. In certain clinical situations, a healthcare professional may use an injectable form, but the tablet is intended for oral administration as directed by a prescriber.

The most serious risks include cardiac arrhythmias such as QT‑interval prolongation, especially in patients with existing heart disease or electrolyte disturbances, and rare cases of severe allergic reactions. Prompt medical attention is required if symptoms like palpitations, fainting, rash or difficulty breathing occur.

Ondansetron should be avoided in patients with known hypersensitivity to the drug or other 5‑HT3 antagonists. Caution is also advised for individuals with congenital long QT syndrome, uncontrolled electrolyte imbalances, or those taking other medications that significantly prolong the QT interval.